Jon LeCroy

In a report published Wednesday, MKM Partners analyst Jon LeCroy reiterated a Buy rating on Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and raised the price target from $26.00 to $32.00. In the report, MKM Partners noted, “Endo International plc (ENDP, $65.17, not covered) announced its proposal...

In a report issued Wednesday, MKM Partners upgraded its rating of Auxilium Pharmaceuticals (NASDAQ: AUXL) from Neutral to Buy with a target price of $26. Analyst Jon LeCroy sees that Testim stabilization and Stendra growth will have a positive impact on the company. LeCroy also estimates an EPS of...

Analyst Jon LeCroy of Hapoalim Securities maintains his "sell" rating on MannKind Corp (NASDAQ: MNKD), while revising his estimates for the company. The target price for MNKD is set to $1. According to Hapoalim Securities, “While MannKind has re-filed Afrezza and received a December PDUFA date, we...

Hapoalim Securities analyst Jon LeCroy reiterated his Buy rating for shares of Arena Pharmaceuticals Inc (Nasdaq: ARNA), with a price target of $6 per share. LeCroy said that Arena Pharmaceuticals (ARNA) presented two pooled analyses at the 2010 ADA meeting that showed that the company's lorcaserin...

Analyst Jon LeCroy of Hapoalim Securities reiterates his "buy" rating on Amylin Pharmaceuticals (NASDAQ: AMLN). The target price for AMLN is set to $22. According to Hapoalim Securities, “Amylin presented data from the DURATION 2 and 5 trials that, in our view, support both the superiority and the...

MannKind Corp. (NASDAQ: MNKD) released a press release discussing the results from its Study 117 comparing Afrezza to Ely Lilly's (NYSE: LLY) injected Humalog. Afrezza is an inhaled insulin intended for treatment of Type I diabetes. At the end of the press release, MannKind mentioned that its End-...

Auxilium Pharmaceuticals' (NASDAQ: AUXL) drug Xiaflex had a disappointing launch. Hapoalim Securities analyst Jon LeCroy is pessimistic about Xiaflex's prospects. Adoption rates will remain slow, and ultimately the product will not penetrate the market as much as previously thought, according to...

Hapoalim Securities healthcare analyst Jon LeCroy maintains his Buy rating for shares of Nektar Therapeutics (NASDAQ: NKTR). Nektar's new cancer drug NKTR-102 is in trials right now, with results expected in mid-2010. "Dr. Verschraegen, who discussed the data, stated that the results were at the...